国际德尔菲研究小组对肥胖患者全膝关节整形术的建议
Ashok Rajgopal1, Dhanasekara Raja Palanisami2, Adarsh Annapareddy3
1Medanta The Medicity, Gurgaon, India.
Archives of orthopaedic and trauma surgery
|March 9, 2026
概括
接受全膝关节整形术 (TKA) 的肥胖患者对管理的专家共识有限. 这项德尔菲研究制定了对肥胖患者TKA的建议,突出了需要进一步研究的领域.
科学领域:
- 整形外科手术 整形外科手术
- 生物医学工程 生物医学工程
背景情况:
- 肥胖症对全膝关节整形术 (TKA) 提出了独特的挑战.
- 在肥胖患者的TKA管理方面存在显著的缺乏共识.
研究的目的:
- 建立有关肥胖患者TKA的专家共识.
- 为改善患者选择和该队列的结果提供建议.
主要方法:
- 一个经过修改的Delphi共识研究,涉及53名国际膝关节外科医生.
- 两轮匿名问卷调查,达成共识的达成协议门为80%.
- 描述性统计数据,包括中位数,用于响应分析.
主要成果:
- 在9个陈述上达成共识,包括世卫组织分类,BMI截止值,骨茎的使用,手术方法和无菌松动的风险.
- 专家小组在17个陈述上没有达成共识,这表明存在重大知识差距.
- 关键建议包括双边TKA的特定BMI截止值和程序之间的时间间隔的必要性.
结论:
- 大多数肥胖患者的TKA管理问题缺乏专家的共识.
- 进一步的研究对于解决证据差距和优化肥胖患者TKA结果至关重要.
- 共识声明为改善患者选择和手术管理提供了基础.
相关概念视频
Drug Dosing: Obese Patients
323
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
323
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
340
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
340
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
259
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
259


